blood smear and bone marrow examination showed no morphologic sign of acute myeloid leukemia (AML) while bone marrow cytogenetic examination by reverse-transcriptase polymerase chain reaction (RT-PCR) evidenced the bcr1 type of the typical PML-RARA fusion transcript. 4 All patients with isolated GS either die shortly after the diagnosis or, in most cases, eventually develop leukemia. 2, 5 Aggressive combination chemotherapy at the time of diagnosis is the only treatment able to prolong life and prevent the subsequent development of leukemia. 5 Our patient was treated with systemic chemotherapy according to the GIMEMA protocol 6 obtaining both complete remission of the promyelocytic sarcomas and the disappearance of the genetic PML-RARA rearrangement in two consecutive bone marrow aspirates; after this therapy, a bone marrow harvest was performed in case of an eventual transplantation. Thirteen months from diagnosis, the patient shows no sign of AML or sarcoma relapse.
The isolated GS often represents a diagnostic dilemma for both the clinician and the pathologist; as a matter of fact, more than 75% of GS are initially misdiagnosed as other neoplasms, mainly as malignant lymphomas, 3 and a correct diagnosis is often made only when lesions recur or leukemia develops. 2 In our case the morphologic and immunohistochemical analysis of the lesion, the molecular findings in the bone marrow together with the response to therapy strongly suggest that GS was infiltrated by leukemic promyelocytes. As far as we are aware, the histologic diagnosis of isolated promyelocytic sarcoma has never been described before. As a matter of fact, in two previously reported cases, a GS was radiologically identified, but not histologically diagnosed, in non-leukemic patients who subsequently developed APL; in both cases histologic diagnosis was made by bone marrow examination after APL development only. 7, 8 More recently, Tosi et al 3 reported a patient affected with undifferentiated epidural GS preceding acute promyelocytic leukemia onset. Thus, this is the first time that a systemic chemotherapy for APL, including ATRA administration, was performed to treat an isolated promyelocytic sarcoma, before leukemia development.
Nowadays, APL is considered a curable disease; we do not know if such a precocious and intensive treatment of our patient could achieve a durable or even definitive remission of the disease.
Myelodysplastic syndrome (MDS) with unbalanced t(1;7) after severe aplastic anemia (SAA) in childhood as a variant form of monosomy 7
TO THE EDITOR Recently, the prognosis of SAA has improved considerably. However, as the number of long-term survivors has been increasing, clonal diseases such as MDS/acute myeloblastic leukemia (MDS/AML) have been observed among these sur- Here we report a pediatric case of MDS with unbalanced t(1;7) (q10;p10) after SAA treated with cyclosporin A (CsA) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). A 1-year-old boy was diagnosed with idiopathic SAA. On admission, the karyotype of BM cells were 46,XY. He was treated with CsA and rhG-CSF. This therapy was continued until complete hematological recovery was obtained (CsA for 29 months and rhG-CSF for 20 months). The total administered dose of rhG-CSF was 17 150 g/body. Two months after cessation of CsA, the patient demonstrated recurrent pancytopenia. At that time, BM showed dysplasia of erythroid and myeloid lineage cells and micromegakaryocytes
Figure 1
Karyotype of BM cells 2 months after diagnosis of MDS shows 48,XY,−7,+der(7)t(1;7)(q10;p10),+8,+21.
were also seen. He was then diagnosed with MDS/refractory anemia (RA), when BM cells showed 46,XY,−7,+der(7)t(1;7)(q10;p10). Two months after diagnosis of MDS/RA, BM cells showed 48,XY,−7,+der(7)t(1;7)(q10;p10),+8,+21, indicating clonal evolution ( Figure 1 ). To confirm the presence of +der (7)t(1;7)(q10;p10) we performed FISH analysis with D1Z5 probe which detects the centromere of chromosome 1. Since the breakpoint of this derivative chromosome is each centromere of both chromosomes 1 and 7, the cell containing this abnormality shows three signals by FISH analysis with D1Z5 probe. As shown in Figure 2 , the majority of BM cells showed three signals. Finally, he received allogeneic bone marrow transplantation (BMT) from his HLA-matched sister. The patient has remained well and free of disease for 25 months after BMT. MDS with unbalanced t(1;7) was first reported by Scheres et al and a number of adult cases has already been reported. Generally, these cases are often therapy-related secondary MDS and associated with poor outcome. However, before this report, only seven childhood and adolescent MDS cases of this translocation had been reported. [3] [4] [5] [6] [7] [8] Patient ages in the reported cases were 11, 14, 15, 15, 16, 16 and 17 years old, respectively, and all of them involved de novo MDS in contrast to adult cases. To our knowledge, this is the first report of pediatric MDS with unbalanced t(1;7) secondary to SAA after CsA plus rhG-CSF therapy at the lowest age (4 years old). Survival data were available in only four pediatric cases with this translocation and reports are not satisfactory (1, 6, 6, 17+ months) . If possible, BMT should be considered for these patients.
In the pathogenesis of monosomy 7, tumor suppressor gene(s) are supposed to be located on the long arm of chromo-
Figure 2
FISH analysis with D1Z5 probe. Three signals were observed. some 7. Therefore, unbalanced t(1;7) is considered a variant form of monosomy 7. Analysis of tumor suppressor gene(s) of monosomy 7 will also clarify the pathogenesis of MDS with unbalanced t (1;7) . The value of c-kit in the diagnosis of biphenotypic acute leukemia
A Kikuchi

TO THE EDITOR
The European Group for the immunological classification of leukemias (EGIL) reported guidelines for the characterization and diagnosis of the various subgroups of acute leukemias on the basis of the expression of lymphoid and myeloid lineage associated markers. 1 One of the aims of the group was to assess the validity and specificity of the detection of some differentiation antigens, which although not widely used, could be potentially useful for lineage assignment. Among others, there was CD117 or c-kit, a monoclonal antibody (McAb) that identifies the receptor for the stem-cell growth factor and which plays an important functional role in hemopoiesis. There were contradictory views with regard to the myeloid specificity of c-kit. Some studies, albeit based on small series of patients, documented a variable proportion of acute lymphoblastic leukemia (ALL) cases to be c-kit+ (for review see Ref.
2). For this reason, in the scoring system to define biphenotypic acute leukemia, c-kit provisionally was given a score of 0.5 point until its probable still uncertain myeloid specificity was demonstrated by testing a large number of ALL samples. 1 We can now establish and confirm the specificity of CD117 (c-kit) for the myeloid lineage supported by our study on close to 2000 acute leukemia cases which included 819 pediatric and adult ALL. 3 Blast cells from only a minority (4%) of ALL expressed c-kit, and most of these cases were very early T-ALL (T-1) and/or had other myeloid features, eg CD13 and/or CD33 expression. Therefore, when considering the scoring system to define biphenotypic acute leukemias, the EGIL proposes to assign to c-kit a score of 1 point for the myeloid lineage as it has been shown to be more specific than CD13 and CD33 which have scores of 1 ( Table 1) . 
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